Angiotensin Therapeutics, Inc.
Publicly observedEvanston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Evanston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Angiotensin Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | XWRYH6QN8JC5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: AGT001 for Delayed Graft Function in Kidney Transplantation
USD 314,355.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: AGT001 for Scleroderma Kidney
USD 295,744.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.